


What is severe allergic asthma?



Asthma is a serious and chronic lung disease.¹
Allergic asthma is the most common form of asthma, accounting for at least **60%** of asthma cases in adults.^{2,3}




Asthma affects an estimated
235 million¹
PEOPLE WORLDWIDE
and affects people of all ages but mostly starts during childhood⁴



8 out of 10
PEDIATRIC PATIENTS
have allergic asthma⁵

Asthma patients have a **reduced quality of life**.⁶



Symptoms include:

- Difficulty Breathing⁴
- Coughing⁴
- Wheezing¹

Allergic asthma can be triggered by:

- Dust⁸
- Pet Dander⁸
- Mold⁸
- Pollen⁸

What is Chronic Spontaneous Urticaria?



Chronic spontaneous urticaria (CSU) is defined as the appearance of hives and/or angioedema without an identifiable trigger for more than **6 weeks**.⁹



Chronic urticaria (CU) affects up to **1%** of the world's population at an given time⁹

CSU accounts for at least two-thirds of cases, with a **female:male** ratio of almost **2:1**⁹

The peak incidence of CSU is seen in people of working age (**20–40 years**), but all age groups can be affected⁹

Symptoms
Occur spontaneously, chronic (lasting for at least 6 weeks)¹⁰

- Red Hives (wheals)¹⁰
- Itch¹⁰
- Deep Tissue Swelling (Angioedema)¹⁰

CSU has a duration of at least **1 year** in most patients and up to **50 years** in some rare cases⁹



Up to **50%** of CSU patients have an inadequate response to H1-antihistamines at licensed doses⁹

An international real-world study showed CU can result in high rates of hospital visits¹¹



1 in 5
patients required
emergency admission¹¹



1 in 3
patients required
hospital admission¹¹



What is Xolair®?



Xolair® (omalizumab) is the only approved biologic designed to target and block immunoglobulin E (IgE). Xolair works by reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation.¹³

The option of self-administration of Xolair could mean:



Less time travelling to/from clinic¹⁴



Less money spent travelling to/from clinic¹⁴



Avoiding hospital-related **infectious exposure risks**¹⁵



Less time away from work or school¹⁴

References:

1. World Health Organization. Asthma. Available at: <http://www.who.int/respiratory/asthma/en/>. Accessed Dec 2018
2. American Academy of Allergy, Asthma & Immunology (AAAAI). Allergic Asthma Definition. Available at: <http://www.aaaai.org/conditions-and-treatments/conditions-a-to-z-search/allergic-asthma.aspx>. Accessed Dec 2018
3. Arbes S. et al. Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007;120:1139-45.
4. National Heart, Lung and Blood Institute. Available at: <https://www.nhlbi.nih.gov/health-topics/asthma>. Accessed: Dec 2018
5. Xolair.com. Allergic asthma treatment guide. Available at: <https://www.xolair.com/content/dam/gene/xolair/PDFs/xolair-allergic-asthma-treatment-guide-caregivers.pdf>. Accessed: Dec 2018
6. VM McDonald et al. Med J Australia 2018;209: S28-S33. Online publication available at: <https://www.mja.com.au/journal/2018/209/2/health-related-quality-life-burden-severe-asthma>
7. Cunha AGJ et al. J Asthm 2018;4:1-6 Abstract available at: <https://www.tandfonline.com/doi/abs/10.1080/02770903.2018.1486854?journalCode=ijas20>. Accessed: Dec 2018
8. Asthma UK. Asthma triggers. Available at: <https://www.asthma.org.uk/advice/triggers/>. Accessed Dec 2018
9. Maurer M, Weller K, Bindslev-Jensen C, et al. Allergy. 2011; 66: 317-330.
10. Novartis UK. The burden of chronic spontaneous urticaria (CSU). Available at: <https://www.novartis.co.uk/sites/stg.novartis.co.uk/files/csui-infographic-2014.pdf>. Accessed: Dec 2018
11. Maurer M, et al. Healthcare resource utilization due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide AWARE study. Poster presented at the EAACI Annual Meeting, June 17-21, 2017; Helsinki, Finland
12. Balp MM, et al. J Eur Acad Dermatol Venereol. 2018;32(2):282-290.
13. Xolair® Summary of Product Characteristics. Novartis Europharm Limited. Available at: Accessed Dec 2018
14. Ghazanfer M and Thomsen S. J Dermatolog Treat 2018; 29(2):196.
15. NICE Guidance. Infection prevention and control. Available at: <https://www.nice.org.uk/guidance/qs61/chapter/introduction>. Accessed: Dec 2018